Age - Related Macular Degeneration (AMD)
14
3
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
14%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
Active AMD Study to Improve Function in Veterans
Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort
Wide Field OCTA in Ocular Diseases
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration
Functional Assessments in Vision Impairment
Development of Novel Clinical Endpoints in Intermediate AMD
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Production of iPSC Derived RPE Cells for Transplantation in AMD
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD